drugset / Trial / NCT05580770
Mirdametinib + BGB-3245 in Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
A Phase 1/2a open-label, multicenter, dose escalation and expansion study of mirdametinib in combination with BGB-3245 in adult participants with histologically confirmed, advanced (American Joint Committee on Cancer (AJCC) Stage III or IV) metastatic or unresectable solid cancer that is refractory to or has progressed during or after at least 1 line of appropriate prior systemic anti-cancer therapy including chemotherapy, immunotherapy, or appropriate targeted therapy, or for which there is no treatment available, or prior standard of care therapy was not tolerated.
Timeline
- Start
- 2023-02-03
- Primary completion
- 2025-01-15
- Completion
- 2025-01-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BGB-3245 | Unknown | 5 mg | Oral |
| Subject | BGB-3245 | Unknown | 10 mg | Oral |
| Subject | BGB-3245 | Unknown | 20 mg | Oral |
| Subject | Mirdametinib | Small molecule | 2 mg | Oral |
| Subject | Mirdametinib | Small molecule | 3 mg | Oral |
| Subject | Mirdametinib | Small molecule | 4 mg | Oral |